Optical coherence tomography (OCT) allows the 3D imaging of skin tissue on a depth scale of ~1-2mm with resolution ~10um. It has been described as an optical analog of ultrasound imaging and offers significantly better resolution than MRI and ultrasound. It has already gained clinical acceptance in ophthalmology and is emerging into other fields such as oncology, monitoring wound healing, cardiology, and guided surgery. The advantages of OCT include:- Video rate images of sub-surface morphology at resolutions ~100 better than ultrasound and voxel rates ~1000 higher than microscopy. Label-free imaging of the sample (in vivo or in vitro). Non-ionizing radiation. Non-contact Endoscopic OCT is ideal for imaging 1~2mm below the surface in biological tissue. Our project is concerned with the development of a prototype swept laser source with 200 - 300 nm sweep range providing sub cellular resolution. We will develop the laser system and trial it in an OCT imagining system.

The Industrial Doctorate Centre in Molecular Modelling and Materials Science (M3S) at University College London (UCL) trains researchers in materials science and simulation of industrially important applications. As structural and physico-chemical processes at the molecular level largely determine the macroscopic properties of any material, quantitative research into this nano-scale behaviour is crucially important to the design and engineering of complex functional materials. The M3S IDC is a highly multi-disciplinary 4-year EngD programme, which works in partnership with a large base of industrial sponsors on a variety of projects ranging from catalysis to thin film technology, electronics, software engineering and bio-physics research. The four main research themes within the Centre are 1) Energy Materials and Catalysis; 2) Information Technology and Software Engineering; 3) Nano-engineering for Smart Materials; and 4) Pharmaceuticals and Bio-medical Engineering. These areas of research align perfectly with EPSRC's mission programmes: Energy, the Digital Economy, and Nanoscience through Engineering to Application. In addition, per definition an industrial doctorate centre is important to EPSRC's priority areas of Securing the Future Supply of People and Towards Better Exploitation. Students at the M3S IDC follow a tailor-made taught programme of specialist technical courses, as well as professionally accredited project management courses and transferable skills training, which ensures that whatever their first degree, on completion all students will have obtained thorough technical and managerial schooling as well as a doctoral research degree. The EngD research is industry-led and of comparable high quality and innovation as the more established PhD research degree. However, as the EngD students spend approximately 70% of their time on site with the industrial sponsor, they also gain first hand experience of the demanding research environment of a successful, competitive industry. Industrial partners who have taken up the opportunity during the first phase of the EngD programme to add an EngD researcher to their R&D teams include Johnson Matthey, Pilkington Glass, Exxon Mobil, Silicon Graphics, Accelrys and STS, while new companies are added to the pool of sponsors each year. Materials research in UCL is particularly well developed, with a thriving Centre for Materials Research and a newly established Materials Chemistry Centre. In addition, the Bloomsbury campus has perhaps the largest concentration of computational materials scientists in the UK, if not the world. Although affiliated to different UCL departments, all computational materials researchers are members of the UCL Materials Simulation Laboratory, which is active in advancing the development of common computational methodologies and encouraging collaborative research between the members. As such, UCL has a large team of well over a hundred research-active academic staff available to supervise research projects, ensuring that all industrial partners will be able to team up with an academic in a relevant research field to form the supervisory team to work with the EngD student. The success of the existing M3S Industrial Doctorate Centre and the obvious potential to widen its research remit and industrial partnerships into new, topical materials science areas, which are at the heart of EPSRC's strategic funding priorities for the near future, has led to this proposal for the funding of 5 annual cohorts of ten EngD students in the new phase of the Centre from 2009.

Traditional pharmaceutical drugs are small molecules that treat the symptoms of a disease. Biopharmaceuticals are larger molecules, for example, peptides and proteins, which target the underlying mechanisms and pathways of a disease that are not accessible with traditional drugs. Recently, there have been rapid and revolutionary developments in this field of biotechnology. Therapeutic peptides and proteins are expected to be used increasingly as vaccines and as treatments for cancer, high blood pressure, pain, blood clots and many other illnesses. However, one of the major challenges to successful clinical use of these so-called "biotech" molecules is their efficient delivery to the site of action. The body breaks these medicines down when they are swallowed and they are generally not well-absorbed into the blood. As a result, they have to be given frequently by injection, which is painful and means that these drugs are usually only administered in hospital. Long-acting formulations of small molecules, increasingly to the fore in treating HIV and TB, must also be injected. The COVID-19 pandemic has greatly increased the need for self-administration of injectables at home, away from healthcare settings, where transmission can have dire consequences. Complexities of storage, distribution and administration, needle phobia and the difficulty of domestic disposal of potentially-contaminated sharps all contribute to an urgent need for alternative delivery modes for injectable drugs/vaccines. Similarly, development of blood-free diagnostic systems is a major priority. We have developed a novel type of transdermal patch that by-passes the skin's barrier layer, which is called the stratum corneum. The patch surface has many tiny needles that pierce the stratum corneum without causing any pain - The sensation is said to feel like a cat's tongue. These needles either dissolve quickly, leaving tiny holes in the stratum corneum, through which medicines can enter the body, or swell, turning into a jelly-like material that keeps the holes open and allows continuous drug delivery. Our unique technology could potentially revolutionise the delivery of peptides and proteins, as well as that of long-acting small molecules that cannot currently be delivered across the skin. Notably, we have also found that our swellable microneedles can extract fluid from the skin. This permits us to monitor the levels of medicines and markers of disease without actually taking blood samples. In the UK, the NHS stands to benefit from reduced costs due to shorter hospital stays and reduced occurrence of inappropriate dosing. Ultimately, health-related-quality-of-life will be enhanced through improved disease control, rapid detection of disease and dangerously high or low levels of medicines, facile monitoring of compliance with prescribed dosing and detection of illicit substances in addicts or vehicle drivers. Preterm neonates will derive great benefit from the marked increase in monitoring frequency permitted, as will elderly patients being treated with multiple medicines. At-home treatment/diagnosis, keeping people away from healthcare settings, will also help reduce spread of COVID-19 to vulnerable in-patients and healthcare workers. We have attracted considerable interest and funding from industry to investigate our technologies for a range of applications. However, to facilitate the commercialisation process and maximise value to the UK, it is now essential to develop methods for rationalised skin application of the microneedles such that they are always applied to every patient in the same way every time and that their efficacy is guaranteed. We will also study, for the first time under industry-standard conditions, repeat application of our microneedles to mimic normal use and to demonstrate safety. Ultimately, commercialisation of the technology will be the primary route by which UK industry, the NHS and patients will derive benefits

Our vision is to bring the power of machine learning and computer vision (also known as 'Artificial Intelligence' or AI) to the application of Optical Coherence Tomography (OCT) imaging of skin, in order to dramatically improve the speed, accuracy and utility of these OCT imaging devices to dermatologists and clinical scientists. At present, end-user clinicians and scientists use OCT imaging devices to capture sub-surface images of skin and then they manually analyse the images to extract data, which is then used to assess the effects of pharmaceutical treatments on skin diseases. OCT imaging is faster, less invasive and less costly than taking skin biopsies, but the image analysis step is still time-consuming, somewhat subjective, and requires observer training. This is a hindrance to the use of OCT imaging to accelerate drug development for skin diseases like skin cancer, atopic dermatitis and psoriasis, which are multi-billion-$ markets. We believe that powerful machine learning algorithms will transform how OCT skin imaging is used by clinical scientists and clinical users to research and develop new drugs. To achieve this vision, we propose seconding a leading expert from AI specialists Manchester Imaging Ltd (MIL) to the host organisation Michelson Diagnostics Ltd, UK SME manufacturer of the world-leading VivoSight Optical Coherence Tomography (OCT) skin imaging and measurement system, over 2 years, to develop and test novel machine learning algorithms for OCT. Key barriers to the wider adoption of OCT for dermatology research is that the OCT images require trained experts to interpret them, and also that the image analysis is somewhat manual in nature. Dermatologists are often time-poor and may not have time to learn how to do this, and the manual nature of the analysis creates potential for unwanted bias. Therefore the challenge is to reduce the barriers to adoption by: Automatically identifying image-markers for common skin diseases Automatically quantifying the image-markers Examples of OCT image-markers requested by Michelson's user base are: Thickened epidermis (Atopic Dermatitis) Loss of definition of dermis-epidermis junction (skin cancer) Detection of tumour 'nests' in the dermis and their invasion-depth/extent (skin cancer) Increase in blood vessel density (all inflammatory diseases) Alterations in blood vessel shape/tortuosity (melanoma) The challenge can only be met by bringing together expertise in AI-algorithms (image processing/machine learning) and OCT imaging technology (laser physics, optics and instrumentation) with close links to the end-user clinical science user base, to form a highly focused and motivated multi-disciplinary team and who will develop and test candidate algorithms on real clinical data.

Optical coherence tomography (OCT) is a new optical bio-imaging tool which is firmly established in ophthalmology and rapidly emerging in areas such as cancer detection, wound monitoring, cardiovascular medicine and tissue engineering. The performance of OCT depends critically on the performance of the light source and the technique's penetration into the wider medical arena is being delayed by the current generation of sources. Our partnership brings together a multidisciplinary team with demonstrated expertise in the entire OCT development chain from photonic device technologists, through biomedical optics researchers, commercial OCT systems manufacturers and clinical end-users into a co-ordinated programme to address this bottleneck. We aim to develop a new generation of light sources which will achieve not only a price/performance breakthrough but also enable much greater system miniaturisation and ruggedness. The new light sources will be evaluated in an active OCT research laboratory and also offered for evaluation by our commercial partners. Next generation OCT imaging systems will be realised by developing optical components and laser systems which will redefine the state-of-the-art with regard to factors such as output power, emission band-width, tuneability of linewidth, sweep speed, and incorporate design features to simplify the OCT system and reduce cost. The research is vertically integrated from the development of new epitaxial techniques, modification of semiconductor materials, device design and fabrication technologies, development of swept laser systems, and their assessment and implementation in OCT systems studying real biological samples.